NAAXIA COLL 10ML 4.9%

NAAXIA 49 MG/ML COLLIRIUM, DEVELOPMENT

active ingredients

1 ml of colliery, solution contains: Active ingredient: N–acetylaspartil–glutamic acid (sodium salt) 49mg (or spaglumic acid). For the full list of excipients, see paragraph 6.1.

Excellent

Sodium hydroxide or hydrochloric acid at pH 7,2 – water for injectable preparations q.b. 10 ml.

Therapeutic indications

Treatment of mild manifestations of conjunctivitis and keratoconjunctivitis of an allergic, acute and chronic nature. Spring conjunctivities.

Contraindications

Hypersensitivity to any of the components of Naaxia collirio, solution without preservative.

Population

Adults and children: instill a drop, from two to six times a day in the joint sack, slightly pulling the lower eyelid down and looking up. Continue therapy throughout the risk period of allergy, even after improvement of symptomatology. Methods of administration The patient must be instructed to: – thoroughly wash his hands before and after instillation, – avoid touching the eye or eyelids with the end of the container. Gently lower the lower eyelid while looking upward, and instill the drop in the eye.

Conservation

Store at a temperature not exceeding 25° C.

Warnings

Clinical studies relating to the use of the product in children under four years of age are not yet available, so Naaxia collirio, a non-preservant solution, must be administered only after careful assessment by the doctor, both of the risks and benefits arising from the therapy. It is recommended not to inject or ingest the product. In severe conjunctiviral allergies antiallergic collides based on N–acetylaspartilglutamic acid may be administered in replacement of initial therapy with cortisonici.Come other ophthalmic specialties for topical use Naaxia collirio, solution without preservative, can be absorbed systemically.

Interactions

The available data does not assume the presence of any significant clinical interaction. In case of contemporary treatment with other collieries, wait 15 minutes between instillation and the other.

Effects

Occasionally, a slight burning sensation may be felt by the patient following instillation; this phenomenon is of short duration and usually disappears with the continuation of therapy. Possible puncture after instillation.

Overdosing

– No case of overdose has been reported. – In case of overdose, rinse with sterile physiological solution.

Clinical studies have not been conducted on the woman in a condition of established or presumed pregnancy. Therefore the product should be prescribed only after careful assessment by the doctor both of the risks and benefits of therapy. There is no data on the passage of the active ingredient in breast milk; breastfeeding is however not recommended during treatment.

Source: Farmadati